Asian Phytoceuticals Public Co., Ltd.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. carries a market capitalization of 1.54B, placing it among publicly traded companies globally. Its enterprise value stands at 1.21B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. has 600.00M shares outstanding.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. trades at a trailing price-to-earnings ratio of 27.16. The price-to-sales ratio is 7.98, and the price-to-book ratio stands at 2.88.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. trades at an EV/EBITDA multiple of 14.31 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 6.14 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 18.54 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. Asian Phytoceuticals Public Co., Ltd. trades at an EV/FCF ratio of 21.66, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.21B versus a market cap of 1.54B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. maintains a current ratio of 13.64, meaning it holds 13.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 1.14, indicating moderate leverage, while an interest coverage ratio of 70.81 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Asian Phytoceuticals Public Co., Ltd. posted a return on equity (ROE) of 10.95, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 9.61 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 9.69, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 10.51, useful for judging operating efficiency across full business cycles. The company generates approximately 1.99M in revenue per employee across its workforce of 99.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 0.43 indicates how many times Asian Phytoceuticals Public Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Asian Phytoceuticals Public Co., Ltd. recorded 13.67M in income tax expense. That works out to an effective tax rate of 18.75, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 72.92M, leaving 57.81M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Asian Phytoceuticals Public Co., Ltd.'s stock has declined approximately 18.83% over the past 52 weeks. The 50-day moving average sits at 2.54, while the 200-day moving average is 2.67.

Over the twelve months ended June 30, 2026, Asian Phytoceuticals Public Co., Ltd. generated 196.68M in revenue and converted that into 57.81M in net income, yielding earnings per share of 0.10. EBITDA reached 84.48M, while operating income came in at 56.84M.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. holds 337.69M in cash and equivalents against 6.15M in total debt, resulting in a net debt position of -231.42M. Total book value stands at 533.10M, with working capital of 386.45M providing operational flexibility.

Asian Phytoceuticals Public Co., Ltd. produced 56.92M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -2.10M in capital expenditures, free cash flow totaled 54.82M - equivalent to 0.09 per share.

Over the twelve months ended June 30, 2026, Asian Phytoceuticals Public Co., Ltd. posted a gross margin of 84.47, reflecting its pricing power and cost economics. The operating margin of 28.90 and net profit margin of 29.39 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Asian Phytoceuticals Public Co., Ltd. paid dividends of 0.09 per share. The dividend payout ratio of 89.98 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 3.49, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 4.62, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Asian Phytoceuticals Public Co., Ltd. shareholders.

Asian Phytoceuticals Public Co., Ltd.'s most recent stock split took place on April 27, 2018 with a 5:1 split ratio.

As of June 30, 2026, Asian Phytoceuticals Public Co., Ltd. has an Altman Z-Score of 17.53, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.